On Nov 05, major Wall Street analysts update their ratings for $Disc Medicine (IRON.US)$, with price targets ranging from $70 to $112.
Morgan Stanley analyst Jeffrey Hung upgrades to a buy rating, and adjusts the target price from $40 to $85.
Wells Fargo analyst Tiago Fauth maintains with a buy rating, and adjusts the target price from $75 to $91.
BMO Capital analyst Evan Seigerman maintains with a buy rating, and adjusts the target price from $70 to $112.
Raymond James analyst Danielle Brill maintains with a buy rating, and adjusts the target price from $50 to $110.
H.C. Wainwright analyst Douglas Tsao maintains with a buy rating, and maintains the target price at $70.
Furthermore, according to the comprehensive report, the opinions of $Disc Medicine (IRON.US)$'s main analysts recently are as follows:
The anticipation for accelerated market entry for Disc Medicine's bitopertin is growing, following positive feedback from an end-of-Phase 2 meeting, which could fast-track its approval based on the existing data. This development increases the likelihood of bitopertin reaching the market sooner and with more certainty. Should accelerated approval be obtained, it would align with more optimistic scenarios for the company's valuation.
Following a favorable regulatory update for bitopertin, the likelihood of its point-of-sale has been increased to 80%, with the anticipation that approval will be expedited using the data already available. This development is seen as a substantial positive, emphasizing the potential for bitopertin to be a genuinely disease-modifying treatment.
Here are the latest investment ratings and price targets for $Disc Medicine (IRON.US)$ from 7 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月5日，多家華爾街大行更新了$Disc Medicine (IRON.US)$的評級，目標價介於70美元至112美元。
摩根士丹利分析師Jeffrey Hung上調至買入評級，並將目標價從40美元上調至85美元。
富國集團分析師Tiago Fauth維持買入評級，並將目標價從75美元上調至91美元。
BMO資本市場分析師Evan Seigerman維持買入評級，並將目標價從70美元上調至112美元。
瑞傑金融分析師Danielle Brill維持買入評級，並將目標價從50美元上調至110美元。
H.C. Wainwright分析師Douglas Tsao維持買入評級，維持目標價70美元。
此外，綜合報道，$Disc Medicine (IRON.US)$近期主要分析師觀點如下：
隨着Disc Medicine的bitopertin獲得2期後會議的積極反饋，加速市場準入的期待正在增長，根據現有數據，該藥有望獲得加速批准。這一進展增加了bitopertin更早更確切地進入市場的可能性。如果獲得加速批准，將符合公司估值更樂觀的情景。
隨着bitopertin獲得有利的監管更新，其銷售點的可能性已提高至80%，預計批准將利用已有數據加速。這一進展被視爲重大利好，強調了bitopertin作爲一種真正的疾病改變性治療的潛力。
以下爲今日7位分析師對$Disc Medicine (IRON.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
